Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 34
1994 35
1995 46
1996 43
1997 40
1998 48
1999 33
2000 34
2001 41
2002 50
2003 40
2004 37
2005 34
2006 39
2007 46
2008 40
2009 32
2010 54
2011 48
2012 36
2013 43
2014 42
2015 39
2016 23
2017 31
2018 42
2019 24
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

968 results
Results by year
Filters applied: . Clear all
Page 1
Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
Muñoz M and Coveñas R. Saudi J Gastroenterol 2016 - Review. PMID 27488320 Free PMC article.
After binding to the neurokinin-1 (NK-1) receptor, the undecapeptide substance P (SP) regulates GI cancer cell proliferation and migration for invasion and metastasis, and controls endothelial cell proliferation for angiogenesis. ...
After binding to the neurokinin-1 (NK-1) receptor, the undecapeptide substance P (SP) regulates GI cancer cell proliferation and migr …
Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach.
Muñoz M and Coveñas R. Anticancer Agents Med Chem 2019 - Review. PMID 29692265
Substance P (SP), through the neurokinin (NK)-1 receptor, controls cancer cell proliferation by activating c-myc, mitogenactivated protein kinases, activator protein 1 and extracellular signal-regulated kinases 1 and 2. ...
Substance P (SP), through the neurokinin (NK)-1 receptor, controls cancer cell proliferation by activating c-myc, mitogenactivated pr …
Substance P and the Neurokinin-1 Receptor: The New CRF.
Schank JR and Heilig M. Int Rev Neurobiol 2017 - Review. PMID 29056150
Substance P (SP) is an 11-amino acid neuropeptide of the tachykinin family that preferentially activates the neurokinin-1 receptor (NK1R). ...
Substance P (SP) is an 11-amino acid neuropeptide of the tachykinin family that preferentially activates the neurokinin-1 receptor (N …
Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists.
Schöppe J, et al. Nat Commun 2019. PMID 30604743 Free PMC article.
Neurokinins (or tachykinins) are peptides that modulate a wide variety of human physiology through the neurokinin G protein-coupled receptor family, implicated in a diverse array of pathological processes. ...Taken together, these co-structures provide a comprehensive structural basis of NK(1)R antagonism and will facilitate the design of new therapeutics targeting the neurokinin receptor family....
Neurokinins (or tachykinins) are peptides that modulate a wide variety of human physiology through the neurokinin G protein-co
Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Rapoport BL, et al. Future Oncol 2018. PMID 29130344
Improved understanding of CINV pathophysiology has triggered the development of new antiemetic therapeutic options, such as selective neurokinin-1 (NK(1)) receptor antagonists (RAs), which effectively prevent CINV when added to a standard antiemetic regimen (serotonin-3 RA and dexamethasone). ...
Improved understanding of CINV pathophysiology has triggered the development of new antiemetic therapeutic options, such as selective neu
Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults.
Karthaus M, et al. Expert Rev Clin Pharmacol 2019 - Review. PMID 31194593
Introduction: The addition of neurokinin-1 receptor antagonists (NK(1)RAs) to standard prophylaxis of 5-hydroxytryptamine-3 RA (5-HT(3)RA) plus dexamethasone more effectively prevents chemotherapy-induced nausea and vomiting (CINV) associated with highly and moderately emetogenic chemotherapy. ...
Introduction: The addition of neurokinin-1 receptor antagonists (NK(1)RAs) to standard prophylaxis of 5-hydroxytryptamine-3 RA (5-HT( …
Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.
Molinos-Quintana A, et al. Invest New Drugs 2019. PMID 29721755
The substance P/neurokinin-1 receptor system has been implicated in tumor cell proliferation. Neurokinin-1 receptor has been identified in different solid tumors but not frequently in hematopoietic malignant cells. We investigated the presence of the Neurokinin-1 receptor in acute myeloid leukemia cell lines (KG-1 and HL-60), demonstrating that acute myeloid leukemia cell lines overexpress the truncated Neurokinin-1 receptor isoform compared with lymphocytes from healthy donors. ...
The substance P/neurokinin-1 receptor system has been implicated in tumor cell proliferation. Neurokinin-1 receptor has been i …
Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis.
Di Maio M, et al. Crit Rev Oncol Hematol 2018 - Review. PMID 29548482 Free article.
According to current ESMO - MASCC guidelines, a combination of a neurokinin-1 receptor antagonist (NK1RA), dexamethasone and a 5-HT3 receptor antagonist (5-HT3RA) is recommended to prevent carboplatin-induced emesis, albeit with moderate level of confidence and not unanimous consensus. ...
According to current ESMO - MASCC guidelines, a combination of a neurokinin-1 receptor antagonist (NK1RA), dexamethasone and a 5-HT3 …
Neurokinin-1 receptor antagonism improves postoperative neurocognitive disorder in mice.
Li Z, et al. Neurosci Lett 2018. PMID 30273701
Emerging evidence suggests that neurokinin-1 receptor (NK-1R), the principal target of proinflammatory neuropeptide substance P (SP), plays a pivotal role in modulating neuroinflammation and BBB integrity. ...
Emerging evidence suggests that neurokinin-1 receptor (NK-1R), the principal target of proinflammatory neuropeptide substance P (SP), …
968 results
Jump to page
Feedback